Vaccitech Newsroom

CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines   Posted on http://cepi.net/node/425 27th September 2018 by Mario Christodoulou   OSLO (Norway), Oxford (UK) CEPI (the Coalition for...

Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Vaccitech Limited, a UK-based company developing products to treat and prevent multiple infectious...

Position Summary Vaccitech is seeking a Project Manager for a hands-on role. The Project Manager will support the manufacturing of our vaccine and therapeutic products, and actively engage with contract manufacturing organisations, contract test labs, and Vaccitech...

View/Download ASCO 2018...

Vaccitech Limited, a UK company developing products to treat and prevent multiple infectious diseases and cancer, today announced the presentation of Phase 1 prostate cancer vaccine data at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. In...

Data on safety and immunogenicity of Vaccitech’s flu vaccine have been presented at the 2018 Annual Conference on Vaccinology Research, run by the National Foundation for Infectious Diseases. The presentation was entitled: A Clinical Study to Determine the Safety and...

The world’s first NHS trial for a universal flu vaccine has recruited its first round of participants, with over 862 people signing up to take part since the trial launched in October 2017. This marks the end of the first phase of the trial, which will open again for...

Vaccitech, an Oxford University spinout company developing a universal flu vaccine, among other vaccine-related products, has secured £20m ($27.1m) in Series A financing. The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences...

The world’s first widespread human testing of a flu vaccine which researchers hope will protect more over 65-year-olds against influenza has begun in the NHS. More than 2,000 people aged 65 and over will be asked to take part in a study supported by the National...

Vaccitech has engaged with Primary Care Clinical Trial Unit at Oxford University to run a small pilot study entitled RIVET (Re-inventing Influenza vaccine Efficacy Trials) as a precursor to its large phase IIb (INVICTUS) novel influenza vaccine study scheduled to...